Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Mallinckrodt
Medtronic
Harvard Business School
Dow

Last Updated: May 24, 2022

VOTRIENT Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Votrient, and when can generic versions of Votrient launch?

Votrient is a drug marketed by Novartis and is included in one NDA. There is one patent protecting this drug.

This drug has forty patent family members in twenty-five countries.

The generic ingredient in VOTRIENT is pazopanib hydrochloride. There are five drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the pazopanib hydrochloride profile page.

DrugPatentWatch® Generic Entry Outlook for Votrient

Votrient was eligible for patent challenges on October 19, 2013.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 19, 2023. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

< Available with Subscription >

  Sign up for a Free Trial

Summary for VOTRIENT
Drug patent expirations by year for VOTRIENT
Drug Prices for VOTRIENT

See drug prices for VOTRIENT

DrugPatentWatch® Estimated Generic Entry Opportunity Date for VOTRIENT
Generic Entry Date for VOTRIENT*:
Constraining patent/regulatory exclusivity:
NDA:
Dosage:
TABLET;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for VOTRIENT

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
National Cancer Institute, FrancePhase 1/Phase 2
Centre Leon BerardPhase 1/Phase 2
medac GmbHPhase 2

See all VOTRIENT clinical trials

US Patents and Regulatory Information for VOTRIENT

VOTRIENT is protected by one US patents.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of VOTRIENT is See Plans and Pricing.

This potential generic entry date is based on patent See Plans and Pricing.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Patents protecting VOTRIENT

Pyrimidineamines as angiogenesis modulators
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 DISCN Yes No See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VOTRIENT

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 See Plans and Pricing See Plans and Pricing
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 See Plans and Pricing See Plans and Pricing
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-002 Oct 19, 2009 See Plans and Pricing See Plans and Pricing
Novartis VOTRIENT pazopanib hydrochloride TABLET;ORAL 022465-001 Oct 19, 2009 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VOTRIENT

See the table below for patents covering VOTRIENT around the world.

Country Patent Number Title Estimated Expiration
South Africa 200304482 PYRIMIDINEAMINES AS ANGIOGENESIS MODULATORS See Plans and Pricing
Hong Kong 1059926 See Plans and Pricing
Hungary 0400691 See Plans and Pricing
Cyprus 1117079 See Plans and Pricing
Portugal 1343782 See Plans and Pricing
China 1307173 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VOTRIENT

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1343782 389 Finland See Plans and Pricing
1343782 SPC/GB10/032 United Kingdom See Plans and Pricing PRODUCT NAME: PAZOPANIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT OR SOLVATE; REGISTERED: UK EU 1/10/628/001 20100614; UK EU 1/10/628/002 20100614; UK EU 1/10/628/003 20100614; UK EU 1/10/628/004 20100614
1343782 2010C/030 Belgium See Plans and Pricing PRODUCT NAME: PAZOPANIB, OPTIONNELLEMENT SOUS LA FORME DE SON SEL PHARMACEUTIQUEMENT ACCEPTABLE OU DE SON SOLVATE; AUTHORISATION NUMBER AND DATE: EU/1/110/628/01 20100616
1343782 C01343782/01 Switzerland See Plans and Pricing FORMER OWNER: GLAXOSMITHKLINE LLC, US
1343782 122010000038 Germany See Plans and Pricing PRODUCT NAME: PAZOPANIB ODER EIN SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/10/628/001-004 20100614
1343782 CA 2010 00024 Denmark See Plans and Pricing PRODUCT NAME: PAZOPANIB, EVENTUELT I FORM AF ET FARMACEUTISK ACCEPTABELT SALT ELLER SOLVAT DERAF, HERUNDER HYDROCLORID
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Baxter
McKesson
Colorcon
Express Scripts
McKinsey
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.